Netherlands· NL-8b8606b2a4e2

Aptivus 250 mg zachte capsules, zachte capsules

A tipranavir product containing tipranavir, registered in Netherlands by Boehringer Ingelheim International GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC J05AE09

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about tipranavirAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Tipranavir is registered in 12 of 19 countries.

Countries holding a registration under ATC J05AE09 (tipranavir), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search tipranavir products by name

Tipranavir · ATC J05AE09

12 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Polandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tipranavir costs, country by country.

Normalised to the WHO defined daily dose (1 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Tipranavir · price per daily dose (1 g)

USD · FX 28 Sept 2026

FR France$30.25

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: TIPRANAVIR
Manufacturer: Boehringer Ingelheim International GmbH
Country: Netherlands (NL)
ATC code: J05AE09
ATC class: Tipranavir
Defined daily dose: 1 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/05/315

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

267 interactions on record for tipranavir.

Graded by severity as the source publishes them — 84 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check tipranavir against other medicines How interaction checks work

Tipranavir · interactions on record

267 records

84 severe
172 moderate
8 info

Most severe, free to view

EluxadolineA07DA06severe
DicoumarolB01AA01severe
WarfarinB01AA03severe
HeparinB01AB01severe

3 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tipranavir in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tipranavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Aptivus
Liechtenstein · Aptivus
Norway · Aptivus

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/986487b1-8f84-4117-9e6b-37c368375a02
GET /v1/drugs/986487b1-8f84-4117-9e6b-37c368375a02?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, zacht",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/aptivus-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Tipranavir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp72727",
  "excipients": [
    "1,4-SORBITAAN",
    "AMMONIA (E 527)",
    "ETHANOL",
    "GELATINE (E 441)",
    "GLYCEROL (E 422)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "LECITHINE (E 322)",
    "MACROGOL 400",
    "MACROGOLGLYCEROLRICINOLEAAT",
    "MANNITOL (D-) (E 421)",
    "MONO- EN DIGLYCERIDEN VAN VETZUREN, MIDDENLANGE KETEN (E 471)",
    "PHOSAL 53 MCT",
    "POLYVINYLACETAAFTALAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "PROPYLEENGLYCOL (E 1520)",
    "PROPYLGALLAAT (E 310)",
    "SORBITOL (E 420)",
    "TITAANDIOXIDE (E 171)",
    "TRIGLYCERIDEN MIDDELLANGE KETEN",
    "TROMETAMOL",
    "WATER, GEZUIVERD",
    "ZWARTE INKT"
  ],
  "substances": [
    "TIPRANAVIR"
  ],
  "leaflet_url": null,
  "authorised_at": "2005/10/25",
  "procedure_number": "EMEA/H/C/000631",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/05/315",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about tipranavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console